Vishal Sharma

Led cross-functional project execution for complex transdermal drug-delivery programs, coordinating R&D, Analytical, QA/RA, Supply Chain, and external CDMO/vendor partners. Developed integrated project plans, risk registers, and milestone trackers to drive on-time delivery of CMC and development milestones.

Spearheaded Voice of Customer (VOC) initiatives to capture insights from pathology KOLs, directly informing assay design and platform roadmap decisions. Engaged KOLs and SMEs to evaluate, test, and refine spatial biology platforms; translated scientific feedback into actionable R&D inputs.

Oversaw development of three advanced forensic genomic assays and one instrument, collectively driving $150M+ in projected revenue. Led seamless integration of Verogen's $200M acquisition into Qiagen's global product portfolio, aligning regional market strategies.

Executed new product introductions (NPI) for ForenSeq® Imagen, ForenSeq® MainstAY SE, and Verogen® PrepStation, generating $100K+ in first-year revenue. Coordinated alpha/beta testing programs with external sites to validate clinical and analytical performance prior to commercial launch.

Drove R&D innovation in single-cell application assays, microfluidic instrumentation, and multi-omics platforms; contributed to Celsee's $150M acquisition by Bio-Rad. Designed novel bead development processes for single-cell assays; introduced streamlined manufacturing methods to improve throughput and reproducibility.

Prototyped 'Celsingle' beads for single-cell genomics; established internal bead manufacturing processes.

Refined microfluidic parameters and optimized 3' gene expression and protein assays on the Genesis platform.

Advanced circulating tumor cell (CTC) capture and enumeration methods; executed a collaborative pilot study with IncellDx.

Delivered scientific presentations and pre-sales demonstrations to clinical and research audiences; contributed to a 510(k) clinical trial for prostate cancer CTC isolation.

Investigated liver-thyroid cross-talk in brown adipose activation; employed AAV and CRISPR methodologies to map metabolic pathways.

Focused on receptor tyrosine kinases as oncology targets; performed xenograft studies and stable transfection assays.

Ph.D. in Biology with a focus on circadian rhythm and cancer biology.

M.S. in Biology with a focus on chromatin biology.

M.Sc. in Life Sciences with a focus on neurosciences.

B.Sc. in Microbiology.